Skip to main content

Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.

Elizabeth M. Whitehorn, Director

Preferred Drug List Process

Upon determination of classes to be reviewed, the department announces the review to the affected manufacturers by E-mail, based on the department’s official Manufacturer Contact List, and posts an announcement on the department’s Web site. The department establishes a review schedule and will announce a due date for offers when the class announcement is made. During the review period, the department’s clinical contractor reviews clinical factors and presents a clinical review to the department. That clinical review is then presented to the Drugs and Therapeutics Advisory Board for their review and recommendations. After the Drugs and Therapeutics Advisory Board makes their recommendations, the department reviews the D&T Board’s recommendations, the clinical review and the financial analysis to make final decisions for the Preferred Drug List. The department then announces the Preferred Drug List decisions.

Manufacturers can submit a supplemental rebate offer by completing the “Manufacturer Contact Form” link above. Additionally, Manufacturers are encouraged to use this link to request a meeting with the Department.

You may register to receive E-mail notification, when a new Preferred Drug List is posted to the Website, by completing the form for for Preferred Drug List E-mail Notification Request.

Inquiries regarding the PDL should be sent via e-mail to Pharmacy.